OBJECTIVES: To determine seroprevalence and determinants of herpes simplex virus 2 (HSV-2) seropositivity, in a random sample of a population based cohort of 10 049 women of Guanacaste, Costa Rica, using a highly sensitive and specific serological assay. METHODS: Seroprevalence was determined by a type specific HSV-2 ELISA assay in an age stratified random sample of 1100 women. Univariate and multivariate logistic regression was used to calculate odds ratios and 95% confidence intervals for risk factors of seropositivity. RESULTS: Overall age adjusted HSV-2 seroprevalence was 38.5% (95% CI, 37.5 to 39.5), and it was strongly associated with increasing age (p(Trend<0.0001)), both among monogamous women and women with multiple sexual partners. A greater number of lifetime sexual partners increased the risk of seropositivity, with a 28.2% (95% CI, 24.4 to 32.2) seroprevalence among monogamous women and 75% (95% CI, 65.6 to 83.0) seroprevalence for those with four or more partners (OR = 7.6 95% CI, 4.7 to 12.4 p(Trend<0.0001)). Barrier contraceptive use was negatively associated with HSV-2 seropositivity (OR 0.54, 95% CI, 0.31 to 0.94). Women with antibodies against HPV 16, 18, or 31 were 1.6 times more likely to be HSV-2 seropositive (OR 1.6, 95% CI, 1.2 to 2.1). CONCLUSIONS: HSV-2 infection is highly endemic in Guanacaste, even among lifetime monogamous women, suggesting a role of male behaviour in the transmission of the infection. Until vaccination against HSV-2 is available, education to prevent high risk sexual behaviour and the use of condoms appear as preventive measures against HSV-2.
OBJECTIVES: To determine seroprevalence and determinants of herpes simplex virus 2 (HSV-2) seropositivity, in a random sample of a population based cohort of 10 049 women of Guanacaste, Costa Rica, using a highly sensitive and specific serological assay. METHODS: Seroprevalence was determined by a type specific HSV-2 ELISA assay in an age stratified random sample of 1100 women. Univariate and multivariate logistic regression was used to calculate odds ratios and 95% confidence intervals for risk factors of seropositivity. RESULTS: Overall age adjusted HSV-2 seroprevalence was 38.5% (95% CI, 37.5 to 39.5), and it was strongly associated with increasing age (p(Trend<0.0001)), both among monogamous women and women with multiple sexual partners. A greater number of lifetime sexual partners increased the risk of seropositivity, with a 28.2% (95% CI, 24.4 to 32.2) seroprevalence among monogamous women and 75% (95% CI, 65.6 to 83.0) seroprevalence for those with four or more partners (OR = 7.6 95% CI, 4.7 to 12.4 p(Trend<0.0001)). Barrier contraceptive use was negatively associated with HSV-2 seropositivity (OR 0.54, 95% CI, 0.31 to 0.94). Women with antibodies against HPV 16, 18, or 31 were 1.6 times more likely to be HSV-2 seropositive (OR 1.6, 95% CI, 1.2 to 2.1). CONCLUSIONS:HSV-2 infection is highly endemic in Guanacaste, even among lifetime monogamous women, suggesting a role of male behaviour in the transmission of the infection. Until vaccination against HSV-2 is available, education to prevent high risk sexual behaviour and the use of condoms appear as preventive measures against HSV-2.
Authors: D T Fleming; G M McQuillan; R E Johnson; A J Nahmias; S O Aral; F K Lee; M E St Louis Journal: N Engl J Med Date: 1997-10-16 Impact factor: 91.245
Authors: M J van de Laar; F Termorshuizen; M J Slomka; G J van Doornum; J M Ossewaarde; D W Brown; R A Coutinho; J A van den Hoek Journal: Int J Epidemiol Date: 1998-02 Impact factor: 7.196
Authors: R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton Journal: Rev Panam Salud Publica Date: 1997-05
Authors: R Herrero; L A Brinton; P Hartge; W C Reeves; M M Breñes; R Urcuyo; M Pacheco; F Fuster; R Sierra Journal: Bull Pan Am Health Organ Date: 1993
Authors: Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk Journal: J Natl Cancer Inst Date: 2010-11-23 Impact factor: 13.506
Authors: Nicolas Wentzensen; Ana Cecilia Rodriguez; Raphael Viscidi; Rolando Herrero; Allan Hildesheim; Arpita Ghosh; Jorge Morales; Sholom Wacholder; Diego Guillen; Mario Alfaro; Mahboobeh Safaeian; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Hoa Van Le; Victor J Schoenbach; Rolando Herrero; Anh Thi Hoang Pham; Hieu Trong Nguyen; Thuy Thi Nguyen; Nubia Muñoz; Silvia Franceschi; Salvatore Vaccarella; Max D Parkin; Peter J F Snijders; Rhoda Ashley Morrow; Jennifer S Smith Journal: Sex Transm Dis Date: 2009-10 Impact factor: 2.830
Authors: Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso Journal: BMC Infect Dis Date: 2009-04-01 Impact factor: 3.090